Perspective Therapeutics (CATX) Net Income towards Common Stockholders (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$28.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders changed N/A year-over-year to -$28.9 million; the trailing twelve-month figure through Mar 2026 stood at -$28.4 million (down 5698.16% YoY), and the FY2025 full-year result was $514000.0, up 154.16% from the prior year.
• Net Income towards Common Stockholders eased to -$28.9 million in Q1 2026, from $514000.0 in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $514000.0 in Q2 2025 to a low of -$28.9 million in Q1 2026.
• A 5-year average of -$4.3 million and a median of -$1.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders sank 234.06% in 2022 and surged 204.9% in 2025, its largest moves.
• Tracing CATX's Net Income towards Common Stockholders over 5 years: stood at -$2.3 million in 2022, then tumbled by 127.82% to -$5.2 million in 2023, then soared by 90.55% to -$490000.0 in 2024, then surged by 204.9% to $514000.0 in 2025, then tumbled by 5727.43% to -$28.9 million in 2026.
• Business Quant data shows CATX's Net Income towards Common Stockholders at -$28.9 million in Q1 2026, $514000.0 in Q2 2025, and -$490000.0 in Q2 2024.